Yulia Slavina

Esperion Therapeutics spotlights 2026 ACC AHA multisociety guideline for dyslipidemia management

Esperion Therapeutics spotlights 2026 ACC AHA multisociety guideline for dyslipidemia management
Esperion on new dyslipidemia guideline

Esperion Therapeutics draws attention to the recently released 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia. The discussion featured Dr. Steve Nissen and Dr. C. Michael Gibson, two prominent figures in cardiovascular medicine.

The new guidelines are expected to influence future approaches in managing cholesterol and cardiovascular risk, providing updated recommendations for clinicians and researchers. Further details on how these guidelines will impact clinical practice are anticipated.

Esperion Therapeutics recently claimed the 88th position on the Financial Times Americas Fastest Growing Companies 2026 list among 300 firms. Earlier this year, the company unveiled key data on NEXLETOL from the CLEAR Outcomes study at the ACC Annual Scientific Session 2026. These developments have placed Esperion in the spotlight during major cardiovascular events.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.